Nanologica AB (publ)

Nanologica's capital structure is characterized by a debt-to-equity ratio of 0.95, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.85, suggesting it can cover short-term obligations but with limited buffer. Free cash flow is negative at -39.93 million SEK, reflecting ongoing operational cash outflows. Profitability metrics are sharply negative, with a return on equity of -226.49% and a return on assets of -58.21%, both significantly below the industry median for Commodity Chemicals. The company reported a net loss of 51.29 million SEK and an operating loss of 46.80 million SEK, indicating a challenging operating environment. Geographically, Nanologica's revenue is concentrated in its home market, with no disclosed international revenue segments. The company's business is entirely disclosed under a single segment, with no diversification across product lines or geographic regions. Growth trajectory is negative, with a year-over-year revenue decline of 62.0% from 55.7 million SEK to 21.13 million SEK. Analysts project a significant revenue contraction in the next fiscal year, with a mean estimate of 83.1 million SEK, which is still below the prior year's performance. Risk factors include liquidity constraints, with negative net cash after subtracting total debt. The company has a low dilution risk, with no near-term pressure from share issuance. However, the operating cash flow of -39.88 million SEK and free cash flow of -39.93 million SEK highlight the need for external financing or operational improvements. Recent events include a 100% consensus among analysts for a price target of 2.97 SEK, unchanged from the previous quarter. The company's last actual EPS was -0.57 SEK, with a mean EPS estimate of 0.00 SEK for the next period, indicating no improvement in earnings is expected.